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COMPARISONS OF EMPLOYEE WORKERS’ COMPENSATION COSTS 
AND ABSENCE DAYS USING A NATIONAL DATABASE
Brook RA1, Kleinman NL2, Melkonian AK3, Smeeding J4
1The JeSTARx Group, Newfoundland, NJ, USA, 2HCMS Group, Paso Robles, CA, USA, 
3HCMS Group, Cheyenne, WY, USA, 4JeSTARx Group, Dallas, TX, USA
OBJECTIVES: To compare the incremental costs and absences due to workers’ com-
pensation (WC) among employees with bipolar disorder (BPD), other mental disorders 
(OMD), chronic constipation (CC), functional dyspepsia (FD), gastroesophageal 
reﬂux disease (GERD), gout, Hepatitis-C (HCV), and insomnia. METHODS: Subjects 
with the study conditions and controls (employees without the condition) were identi-
ﬁed in a 2001–2007 US Employee Database. All studies used two-part regression 
models to control for differences between employees and controls. WC costs included 
salary replacement payments made to the employee and associated medical payments 
(adjusted to 2007 US$). Absences were based on days missed during the WC claim. 
Index dates were the date of the employees’ ﬁrst diagnosis (by condition). Controls 
(by study) used the average index date of subjects with the condition. Incremental 
costs and absences were deﬁned as adjusted differences between the condition cohort 
and controls and considered signiﬁcant at P ≤ 0.05. RESULTS: Employees with WC 
eligibility varied from 339 to 17,714 in the condition cohorts and from 120,465 to 
292,631 in WC control groups. All incremental WC cost differences between condi-
tion and control cohorts were signiﬁcant except incremental costs associated with FD 
(P > 0.05). Gout had the highest incremental annual costs ($813), while GERD had 
the most annual incremental absence days (0.80). FD had the lowest incremental WC 
costs (−$377) and absence days (−0.36). CONCLUSIONS: Most of the conditions 
studied were associated with signiﬁcant incremental WC costs and absence days, even 
though they are not thought of as common workplace injuries or illnesses. Employees 
with GERD were among those with the highest incremental WC costs and days absent. 
Further research is required to determine if the incremental WC costs and days occur 
because these conditions cause employees to be more susceptible to workplace injury 
or if they occur because employees with these conditions are more knowledgeable 
about using health beneﬁts.
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THE FINANCIAL IMPACT OF MEDICATION RECONCILIATION TO 
REDUCE DRUG-RELATED PROBLEMS
Lin YM, Tsai SC, Shiau YF, Leu WJ, Liu HP
Taipei Medical University- Shuang Ho Hospital, Jhonghe City, Taiwan, Taiwan
OBJECTIVES: Medication reconciliation is the process to compare patients’ existing 
and previous medication regimens to identify and avoid medication errors. All medica-
tions should be appropriately and consciously continued, discontinued, or modiﬁed 
at all transitions of care. The objective of this study is to implement medication rec-
onciliation at admission to reduce drug-related problems and to evaluate the ﬁnancial 
impact of these approaches in Taiwan. METHODS: The patients admitted to the local 
hospital and stayed more than three days were recruited in this study, while the 
patients with cancer or admitted to the ICU were excluded. Next, pharmacists 
reviewed the charts of admitted patients and compared the medication regimens at 
present and before admission. Once the unreconciled medications were identiﬁed, 
pharmacists would discuss with the physicians to ensure if therapy should be adjusted. 
The determination of ﬁnancial impact is expressed by cost avoidance per year in 
Taiwan. RESULTS: The data from our study suggests that between 5% and 10% of 
drug-related problems were identiﬁed and prevented by pharmacists through the 
process of medication reconciliation. This can translate into between 158,400 and 
316,800 episodes per year in Taiwan (based on the assumption for total hospitaliza-
tion of about 3,168,000 persons per year). The estimated cost avoidance will be as 
high as NT 792 million to 1584 million per year (based on the assumption that cost 
of prolonged length of hospital stay is about NT 5000) through executing the medica-
tion reconciliation at admission. CONCLUSIONS: This study demonstrated that the 
pharmacists’ interventions were able to prevent potential adverse drug events and 
reconcile discrepancies among medication, as well as reduce medical expenditure. 
Effective assurance in medication safety is achieved through the collaboration of 
patient care team.
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PHYSICIANS’ PERCEPTION OF MEDICAID PAYMENTS AND 
WILLINGNESS TO ACCEPT NEW MEDICAID PATIENTS
Kaisaeng N1, Matzke GR1, Zhang J2
1Virginia Commonwealth University, Richmond, VA, USA, 2Virginia Commonwealth 
University, Richmond, VA, USA
OBJECTIVES: We sought to assess how physicians’ perceptions of Medicaid payments 
inﬂuenced their willingness to accept new Medicaid patients. METHODS: The physi-
cian component of 2004–2005 Community Tracking Survey, which included a total 
of 6628 physician respondents was analyzed. Multivariate regression analysis was 
performed to assess physicians’ willingness to accept new Medicaid patients on the 
three sets of covariates: a) physician characteristics, b) perception of Medicaid pay-
ments; and c) information technology used in practice. RESULTS: Hospital-based 
physicians and physicians of non-white races are more likely to accept new Medicaid 
patients (adjusted odds ratio (OR) 1.25, p = 0.038 and OR 1.72, p = 0.005, respec-
tively), compared to solo practice and white physicians, respectively. In addition, 
surgeons and specialists were more likely to accept new Medicaid patients compared 
to primary care physicians (adjusted OR 5.31, p < 0.0001; and adjusted OR 3.87, p 
< 0.0001, respectively). Physicians’ acceptance of new Medicaid patients was positively 
associated with the amount of hours spent with patients per week (adjusted OR 1.01, 
p = 0.001) and the hours of charity care provided (adjusted OR 1.01, p = 0.018). The 
acceptance of new Medicaid patients was negatively associated with the perceptions 
of Medicaid payment issues, including billing and paperwork requirement and ﬁling 
of Medicaid claims (adjusted OR 0.60, p < 0.0001), inadequate Medicaid reimburse-
ment (adjusted OR 0.77, p = 0.014) and delayed Medicaid reimbursement (adjusted 
OR 0.72, p = 0.002). The perception of lack of specialists in the service area was 
positively associated with the physicians’ willingness to accept new Medicaid patients 
(adjusted OR 1.35, p = 0.033). The availability of information technology, such as 
electronic prescribing, was not associated with physicians’ willingness to accept new 
Medicaid patients. CONCLUSIONS: The factors which signiﬁcantly inﬂuenced physi-
cians’ willingness to accept new Medicaid patients included several dimensions in 
Medicaid payments. Regulators and policymakers need to be aware of the possible 
unintended consequences of cost containment policy actions which may negatively 
impact access to care by Medicaid patients.
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POTENTIAL SAVINGS FROM BROAD USE OF $4 GENERIC DRUGS:  
2007 MEDICAL EXPENDITURE PANEL SURVEY
Zhang Y1, Zhou L1, Gellad W2
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OBJECTIVES: Generic drugs are bioequivalent to brand-name drugs but cost sub-
stantially less. Several retailers offer generic drugs at $4/30-day-supply. Little is known 
on how $4 programs are used or potential savings from broad use of these generics. 
Our study ﬁlls this gap. METHODS: The 2007 Medical Expenditure Panel Survey 
(MEPS) includes all prescribed medications used by a nationally-representative sample 
of 30,964 individuals. We identiﬁed a list of generic formulations commonly available 
at $4 generic-drug programs and identiﬁed MEPS respondents who used these drugs. 
We compared characteristics between those who paid $4 in 2007 for their generics vs 
those who could potentially have saved by switching to $4 programs. For the latter, 
we calculated potential total annual savings. RESULTS: Among 7133 adults who used 
generics available in $4 programs, 5.9% paid $4 and 66.5% could potentially have 
saved by switching to a $4 generic program, corresponding to 50,292,349 US individu-
als. Compared to those who appeared to use $4 programs in 2007, those who could 
save were more likely to be male (42.7% vs. 32.5%, p < 0.05), middle/high- income 
(75% vs 70%, p < 0.05), and have zero chronic condition (51.4% vs. 44.3%, p < 
0.05). If patients had used $4 programs, annual savings per-person would be $66.22 
(s.e. = $2.43) in 2007, of which $38.50 (s.e. = 1.57) would be savings by patients, 
$16.46 (s.e. = 1.33) by private health plans, and $10.22 (s.e. = 1.07) by Medicare. 
This translates into $3 billion in total annual savings in the US: $1.9 billion by patients, 
$0.8 billion by private insurance, and $0.5 billion by Medicare. CONCLUSIONS: 
Total annual savings of $3 billion was possible in the US in 2007 if patients had used 
$4 programs. This is the lower bound of potential savings because it does not capture 
savings if patients switch from brand-name drugs to equivalent $4 generics.
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OBJECTIVES: To analyze the market situation of extremely low-priced drugs with 
the National Health Insurance in Taiwan. METHODS: The analysis was limited to 
the ambulatory setting. The data sources came from the claims datasets of prescrip-
tions dispensed at contracted pharmacies (GO, complete) and at hospitals and clinics 
(OO, 1/500 sampling) in 2007, offered by the National Health Insurance Research 
Database in Taiwan. For favorable comparisons, the focus was on oral drugs with 
solid forms, e.g. tablets and capsules. A cheap drug was deﬁned as with a unit price 
<= 1 New Taiwan dollar (NTD), about 0.03 US dollar. RESULTS: During the year, 
13,594 distinct drug items had been prescribed 803,961,618 times with total expen-
diture of 87,794,653,006 NTD. Among them, 8,795 oral drug items accounted for 
687,629,169 prescribed items (85.5% of total prescribed items) and 63,177,684,194 
NTD (72.0% of total drug expenditure). According to the last price of each oral drug 
item at the end of 1997, the average unit price was 10.3 +/− 92.4 NTD, with minimum 
0.06, maximum 4,111, median 1.5, 25 percentile 0.8 and 75 percentile 4.3, and 2,873 
items (32.7% of oral drug items) had a unit price <= 1 NTD. While the top one item 
among all oral drugs had already a market share of 5.2%, 19 items 25% and 99 items 
50%, the cheap drugs with aggregate frequency of 323,571,583 prescribed items 
(47.1% of all prescribed oral drug items) only accounted for 2,583,591,026 NTD 
(4.1% of expenditure for oral drugs and 2.9% of total drug expenditure). CONCLU-
SIONS: The drug market of the National Health Insurance in Taiwan was abundant 
in cheap drugs. The unreasonably low prices of drugs might not guarantee the quality 
of pharmaceutical care and the sustainability of a healthy pharmaceutical industry in 
the long run.
